Myeloproliferative Neoplasms Clinical Trial
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Summary
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
Eligibility Criteria
Key Inclusion Criteria:
Diagnosis of PMF or Post PV/ET-MF
Requires myelofibrosis therapy, in the opinion of the investigator
High risk OR intermediate-2 risk defined by dynamic international prognostic scoring system (DIPSS) OR intermediate-1 risk defined by DIPSS and associated with symptomatic splenomegaly and/or hepatomegaly
Transfusion dependent at baseline, defined as ≥ 4 U red blood cell (RBC) transfusion in the 8 weeks prior to first dose of MMB
Acceptable organ function as evidenced by the following:
Platelet Count ≥ 50 x 10^9/L
Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x upper limit of normal (ULN) or AST or ALT ≤ 5 x ULN if liver is involved by disease process as judged by the investigator
Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance of ≥ 60 mL/min
Direct bilirubin ≤ 2.0 x ULN
Life expectancy of > 24 weeks
Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
Lactating females must agree to discontinue nursing before MMB administration
Able to understand and willing to sign the informed consent form
Key Exclusion Criteria:
Prior splenectomy
Splenic irradiation within 3 months prior to the first dose of MMB
Prior treatment with MMB
Known positive status of human immunodeficiency virus (HIV)
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Use of strong cytochrome P450 3A4 (CYP3A4) inducer within 2 weeks prior to the first dose of MMB
Uncontrolled intercurrent illness per protocol
Treatment with a Janus kinase (JAK) inhibitor within 21 days of the planned first dose of MMB
Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
Unwilling or unable to undergo a MRI per requirements in the study protocol
Unwilling to consent to genomics sampling
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Phoenix Arizona, , United States
Los Angeles California, , United States
Orange California, , United States
Jacksonville Florida, , United States
Baltimore Maryland, , United States
Ann Arbor Michigan, , United States
Saint Louis Missouri, , United States
Bronx New York, , United States
New York New York, , United States
Durham North Carolina, , United States
Cleveland Ohio, , United States
Houston Texas, , United States
Toronto Ontario, , Canada
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.